GBI Research, the leading business intelligence provider, has released its latest research "Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington's Disease Segment", which provides insights into the CNS orphan disease therapeutics market until 2017. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. The report provides an in-depth analysis of amyotrophic lateral sclerosis, huntington's disease and myasthenia gravis. It also provides the share of generics in global CNS orphan disease therapeutics and in each indication market. The report examines the global orphan diseases therapeutics in CNS usage patterns. It includes the geographical distribution of amyotrophic lateral sclerosis, huntington's disease and myasthenia gravis markets across the US, the top five countries of Europe and in Japan. The report also includes insights into the orphan diseases therapeutics in CNS Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the CNS orphan disease therapeutics market. Finally, the report includes analysis on Mergers and Acquisitions (M&A) and licensing agreements that took place in the orphan diseases therapeutics in CNS market.
GBI Research's analysis shows that the overall global CNS orphan disease market is set to increase over the forecast period. It grew from $359.6m in 2002 to $665.5m in 2010 at a Compound Annual Growth Rate (CAGR) of 8%. This is projected to increase to a CAGR of 17.6% over the forecast period to $2.1 billion in 2017. The global ALS therapeutics market generated approximately $163.2m in 2010, growing from $109.7m in 2002 at a CAGR of 5.1%. By 2017, this is expected to have increased to $210.5m at a CAGR of 3.7%. ALS was one of the biggest orphan CNS disease markets globally in 2010. The global HD therapeutics market generated approximately $126.7m in 2010, growing from $34.3m in 2002 at a CAGR of 17.8%. By 2017, this is expected to have increased to $786.5m at a CAGR of 29.8%. Globally, the MG therapeutics market increased from $42.5m in 2002 to $57.7m in 2010 at a CAGR of 3.9%. Over the forecast period it is expected to grow to $88.6m in 2017 with a higher CAGR of 6.3%.
The report will assist business development and marketing executives to strategize their product launches, by allowing them to -